Glaukos Corporation $GKOS Shares Acquired by California State Teachers Retirement System

California State Teachers Retirement System lifted its holdings in Glaukos Corporation (NYSE:GKOS - Free Report) by 13,483.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,024,303 shares of the medical instruments supplier's stock after purchasing an additional 8,957,869 shares during the period. California State Teachers Retirement System owned about 15.30% of Glaukos worth $1,261,237,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of GKOS. BlackRock Inc. purchased a new stake in Glaukos in the 2nd quarter worth $1,333,318,000. Janus Henderson Group PLC grew its position in shares of Glaukos by 77.2% in the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier's stock valued at $575,844,000 after purchasing an additional 2,329,608 shares during the period. Jupiter Topco LLC purchased a new stake in shares of Glaukos during the second quarter worth about $679,614,000. Wellington Management Group LLP increased its stake in shares of Glaukos by 10.4% during the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier's stock worth $292,004,000 after purchasing an additional 336,266 shares in the last quarter. Finally, Primecap Management Co. CA raised its position in shares of Glaukos by 49.8% during the 4th quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier's stock worth $381,289,000 after purchasing an additional 1,123,140 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Insider Buying and Selling at Glaukos

In related news, Director Gilbert Kliman sold 2,500 shares of the business's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total transaction of $475,000.00. Following the completion of the transaction, the director directly owned 37,406 shares of the company's stock, valued at $7,107,140. The trade was a 6.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Alex Thurman sold 20,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the sale, the chief financial officer owned 43,906 shares in the company, valued at $7,908,787.78. The trade was a 31.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 113,025 shares of company stock worth $19,600,006. 5.90% of the stock is currently owned by insiders.

Glaukos Trading Down 1.8%

Shares of Glaukos stock opened at $167.35 on Friday. The firm has a market capitalization of $9.87 billion, a price-to-earnings ratio of -51.49 and a beta of 0.76. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $191.62. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The stock has a 50 day moving average of $170.04 and a 200 day moving average of $138.49.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same period in the previous year, the firm earned ($0.24) EPS. Glaukos's revenue was up 49.6% on a year-over-year basis. As a group, research analysts predict that Glaukos Corporation will post -0.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several research reports. UBS Group began coverage on Glaukos in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $150.00 target price on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Glaukos in a research report on Friday, July 17th. Wells Fargo & Company increased their price objective on Glaukos from $138.00 to $178.00 and gave the company an "overweight" rating in a research note on Thursday, July 30th. Truist Financial raised their price objective on Glaukos from $180.00 to $215.00 and gave the company a "buy" rating in a report on Thursday, July 30th. Finally, BTIG Research lifted their target price on shares of Glaukos from $193.00 to $202.00 and gave the stock a "buy" rating in a research note on Thursday, August 20th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $178.08.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company focused on developing and commercializing products designed to treat glaucoma, corneal disorders and other eye conditions. The company's technologies are intended to provide alternatives to traditional treatments and support earlier intervention in the management of progressive eye disease.

Glaukos is best known for its portfolio of micro-invasive glaucoma surgery products, including the iStent family of implantable devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.